In a report released on November 18, Jason Kolbert from Dawson James maintained a Hold rating on Kintara Therapeutics (KTRA – Research Report). The company’s shares closed last Friday at $4.01.
According to TipRanks, Kolbert is an analyst with an average return of -5.1% and a 33.42% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as BioCardia, Can-Fite BioPharma, and Daré Bioscience.
Kintara Therapeutics has an analyst consensus of Hold.
See the top stocks recommended by analysts >>
The company has a one-year high of $42.08 and a one-year low of $3.67. Currently, Kintara Therapeutics has an average volume of 56.84K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Read More on KTRA:
